Page 150 - 30917_ASHG_Complete

This is a SEO version of 30917_ASHG_Complete. Click here to view full version

« Previous Page Table of Contents Next Page »
Saturday, October 15
1:30
PM
–3:30
PM
Concurrent Platform Session D (68-77)
SESSION 76 – Genetic Screening and Education
Room 710B, Level 7, Convention Center
Moderators:
Giovanni Romeo, Univ. of Bologna, Italy;
Andrew Faucett, Geisinger Genome Med. Inst.., USA
309
/1:30
Genetic counsellor education and
professional standing in 17 European countries.
C.
Cordier, U. Hosterey-Ugander, D. Lambert, M. A.
Voelckel, H. Skirton.
310
/1:45
Differences observed in the
communication of breast cancer risk factors
among European GPs and breast surgeons.
C. M.
Julian-Reynier, D. G. R. Evans, A. D. Bouhnik, H.
Harris, C. Van Asperen, A. Tibben, J. Schmidtke, I.
Nippert.
311
/2:00
Estonian public attitude towards and
expectations for personalized medicine.
L. Leitsalu,
A. Allik, A. Metspalu.
312
/2:15
First trimester screening, it’s not a routine
test: An education module for general practitioners
to help women to make an informed choice.
K.
Dunlop, K. Barlow-Stewart.
313
/2:30
Increasing the ability to predict
FMR1
repeat instability: Regression analysis of CGG/AGG
structure in 546 transmissions from parents with
45-69 CGG repeats.
E. G. Allen, S. L. Sherman, S. L.
Nolin, A. Glicksman, E. Berry-Kravis, F. Tassone, C.
Yrigollen, A. Cronister, M. Jodah, N. Ersalesi, W. T.
Brown, R. Shroff, S. Sah, G. J. Latham, A. G. Hadd.
314
/2:45
Twenty-six years of prenatal testing for
Duchenne and Becker muscular dystrophy in the
Netherlands: Has it made an impact?
A. T. J. M.
Helderman-van den Enden, K. M. Madan, M. H.
Breuning, A. H. van der Hout, E. Bakker, C. E. M. de
Die-Smulders, H. B. Ginjaar.
315
/3:00
Tryptic peptide analysis of WBC to
diagnose genetic disorders: Application to primary
immunodeficiency disorders and nephropathic
cystinosis.
S. Hahn, S. Kerfoot, S. Jung, V. Vasta, K.
Golob, T. Torgerson, T. Vilboux, W. Gahl.
316
/3:15
Genetic test evaluation models: How well
do they fit the translational process?
F. E. Caballero,
R. N. Battista, A. M. Laberge.
Cameras and all other recording devices are
strictly prohibited
in all session rooms. Thank you for your cooperation
Saturday, October 15
1:30
PM
–3:30
PM
Concurrent Platform Session D (68-77
SESSION 77 – Cancer Genetics III: Susceptibility to
Outcome
Room 510, Level 5, Convention Center
Moderators:
Thomas J. Hudson, Ontario Inst. for
Cancer Res., Canada; Johji Inazawa, Tokyo Med. &
Dent. Univ., Japan
317
/1:30
A replication study examining novel
common single nucleotide polymorphisms
identified through a prostate cancer genome-wid
association study in a Japanese population.
J.
Batra, F. Lose, S. Chambers, R. Gardiner, J. Aitkin,
Yaxley, J. Clements, A. Spurdle, Australian Prostate
Cancer BioResource.
318
/1:45
Polymorphisms in MMPs, TIMPs, and
RECK interact to influence susceptibility to
prostate cancer and aggressive disease among
two groups of African American men.
W.
Hernandez, S. Hooker, R. Kittles.
319
/2:00
Exome sequencing reveals sequential
alterations of cancer driver genes during
progression of metastatic prostate cancer.
M. L.
Nickerson, K. M. Im, K. J. Misner, A. L. Yates, D. W.
Wells, H. C. Bravo, K. Fredrikson, W. Tan, M. Yeage
P. Milos, B. Zbar, G. S. Bova, M. Dean.
320
/2:15
Genomic signatures of metastasis in
prostate cancer.
A. Pearlman, C. Campbell, E.
Brooks, A. Genshaft, S. Shajahan, M. Ittmann, G.
Bova, J. Melamed, I. Holcomb, R. Schneider, Y. Sha
H. Ostrer.
321
/2:30
Most, but not all, common risk alleles fo
colorectal cancer act through predisposition to
adenomas.
L. G. Carvajal-Carmona, A. G. Zauber,
M. Jones, J. Wang, D. Morton, M. M. Bertagnolli, I.
Tomlinson.
322
/2:45
Variation in epigenetic regulatory
pathways and breast cancer susceptibility.
T.
Kirchhoff, J. Rendleman, Y. Antipin, B. Reva, C.
Sander, M. M. Gaudet, R. J. Klein, K. Offit.
323
/3:00
Alteration of
PBRM1
and
VHL
in clear c
renal cancer.
M. Dean, K. M. Im, K. Misner, D. Well
B. Gold, L. S. Schmidt, B. Zbar, N. Rothman, W.-H.
Chow, F. Waldman, W. M. Linehan, L. E. Moore, M.
Nickerson.
324
/3:15
A new disease: Retinoblastoma driven b
MYCN
amplification with normal
RB1
tumor
suppressor gene alleles.
B. L. Gallie, D. E. Rushlo
S. Yee, J. Y. Kennett, P. Boutros, N. L. Prigoda-Lee,
Halliday, S. Pajovic, C. Spencer, B. L. Thériault, H.
Dimaras, A. Raizis, C. Houdayer, D. Lohmann.